Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206642 | 0.94 | MAPK1 (0.47) | PRMT5CYP3A4CHEK2MAPK1MEN1 | |
| SCHEMBL10206644 | 0.93 | PRMT5 (0.46) | PRMT5CYP3A4CHEK2ALOX5PTGES | |
| SCHEMBL709496 | 0.91 | PRMT5 (0.44) | PRMT5CYP3A4CHEK2ALOX5PTGES | |
| SCHEMBL2668247 | 0.90 | CYP1A1 (0.44) | PRMT5CYP3A4CHEK2MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL712377 | 0.90 | CHEK2 (0.45) | PRMT5CYP3A4CHEK2MEN1KMT2A | |
| SCHEMBL10206640 | 0.90 | PRMT5 (0.43) | PRMT5CYP3A4CHEK2 | |
| SCHEMBL10206646 | 0.89 | CYP3A4 (0.43) | PRMT5CYP3A4CHEK2MAPK1MEN1 | |
| SCHEMBL10206647 | 0.88 | CYP3A4 (0.42) | PRMT5CYP3A4CHEK2MAPK1DHODH | |
| SCHEMBL711039 | 0.87 | PRMT5 (0.41) | PRMT5CYP3A4CHEK2MEN1KMT2A | |
| SCHEMBL2086747 | 0.87 | PRMT5 (0.41) | PRMT5CYP3A4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | PRMT5 2373/4885CYP3A4 193/4885CHEK2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.